New combo pill aims to tackle diabetes and fatty liver at once
NCT ID NCT07289750
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This phase 4 trial will test whether adding alogliptin to a standard two-drug regimen (pioglitazone and metformin) improves blood sugar control and liver health in 80 adults with type 2 diabetes and fatty liver disease. Participants must not have used diabetes medications in the past six months. The study compares the three-drug combo against the two-drug combo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAFLD are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alogliptin, pioglitazone, and metformin hydrochloride tablets
What this could lead to
If successful, this could point to a more effective combination therapy for managing both type 2 diabetes and fatty liver disease.
What could go wrong
This is a small, early-phase trial (80 participants) that has not yet started. The added benefit of alogliptin may be modest, and results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.